|
2nd International School on In Silico Trials 6 -10 September 2021 online, every afternoon from 15 to 19 CEST
In the past few years, it became possible, in some cases, to provide evidence of safety and efficacy for new medical products using modelling and simulation, what is now referred to as In Silico Trials.
This could be a game-changer, but it is also a disruptive innovation that may require some changes in the business model of many companies.
The 2nd International School on In Silico Trials will offer a systematic, non-specialist review on the strengths and the weakness of in silico trials technologies. The participants will be guided in the development of a better and deeper understanding of the threats and opportunities that this unprecedented technology presents, with the goal to enable more informed decision-making on the adoption of these innovations.
The school this year is organized by methods. After an introduction of the Director Prof. Marco Viceconti, a world-class expert will present a specific modelling method, illustrate it around a specific exemplar use case, and provide a critical review of the pros and cons of such method. We will lecture on molecular dynamics, systems biology, machine learning, computational fluid dynamics, finite element modelling, and agent-based modelling. We will also lecture on the use of high-performance computing, and the challenges posed by multiphysics and multiscale models. We will close with a systematic SWOT analysis of the adoption of In Silico Trials in the average biomedical company, and a review of the current regulatory landscape. |
|
|
| | |
| |
- Postdoc opportunity in Bologna
|
|
- Upcoming Avicenna Alliance webinar |
| | | |
|
|
- VPHi keynote webinar: How to write a scientific paper. Webinar recordings and slides |
| | | | |
- MaCSBio Science Day 2021 |
| |
- Compbiomed Conference: building the virtual human |
| | |
|
| |
ARE YOU NOT A VPHi MEMBER YET? Join us |
| "The Virtual Physiological Human will revolutionise the way health knowledge is produced stored and managed as well as the way in which healthcare is currently delivered." European Commission |
| |
|
|